Low carbon pMDIs Bespak is actively developing and commercialising low carbon pressurized metered dose inhalers (pMDIs), signaling a focus on sustainable device solutions. Sales opportunities exist in partnering on carbon-minimised inhaler programs and accreditation for climate-friendly products.

Expanded manufacturing capacity Recent partnership expansion with Chiesi to increase pMDI manufacturing capacity at the Holmes Chapel site indicates growing demand and potential for multi-year supply agreements, tooling upgrades, and scale-ready contracts.

Sustainability commitments Bespak has engaged in biodiversity footprint assessment and climate-friendly transitions through collaborations with environmental and sustainability programs. This creates a gateway for customers seeking verified ESG alignment and sustainable sourcing in device manufacturing.

Strategic leadership Appointment of a high-profile pharma leader as chairman and ongoing leadership to steer CDMO services positions Bespak to win partnerships with global pharma players pursuing advanced inhalation platforms and device integration capabilities.

Growth and hiring momentum Headcount expansion and the potential for additional roles in Holmes Chapel reflect capacity to support larger programs, higher volumes, and faster time-to-market—visiting opportunities for growth-oriented clients needing scalable CDMO partnerships.